摘要
目的探究吉西他滨与培美曲塞分别联合顺铂治疗非小细胞肺癌的临床疗效。方法80例非小细胞肺癌患者均选自我院2016年2月至2018年4月,依据随机数字表方法平均划分为观察组以及对照组,40例对照组患者采用吉西他滨联合顺铂治疗,40例观察组采用培美曲塞联合顺铂治疗,对比两组患者的临床疗效。结果①观察组患者和对照组经过治疗后其总有效率计算后为90%和82.5%,两组数据对比P>0.05;②比较观察组和对照组患者治疗后CA125、CEA以及NSE水平,观察组更具优势,P<0.05;③观察组和对照组患者治疗后IL-27、TGF-β1以及MMP-2经统计对比,组间数据差异显著,P<0.05。结论吉西他滨与培美曲塞分别联合顺铂治疗非小细胞肺癌效果具有一定的相似性,然而培美曲塞联合顺铂对患者经进行治疗可将其肿瘤标志物改善,值得予以临床推广。
Objective to explore clinical curative effect of gemcitabine and pemetrexed combined with cisplatin in treatment of non-small cell lung cancer(NSCLC).Methods divide 80 cases NSCLC patients from February 2016 to April 2018 in our hospital into observation group and control group according to random number table method.40 cases in control group were treated with gemcitabine combined with cisplatin,and 40 cases in observation group with pemetrexed combined with cisplatin.Compare clinical effect of two groups.Results①total effective rate of observation group and control group was 90%and 82.5%after treatment,and data comparison showed P>0.05 between two groups.②CA125,CEA and NSE level on observation group had more advantages than control group after treatment,P<0.05.③IL-27,TGF-beta 1 and MMP-2 levels difference after treatment showed statistical significance between observation group and control group,(P<0.05).Conclusion gemcitabine and pemetrexed combined with cisplatin respectively in treatment of non-small cell lung cancer have some certain similarity,but pemetrexed combined with cisplatin can improve tumor markers of patients after treatment,which is worthy of clinical promotion.
作者
李莉
彭友
LI Li;PENG You(Shehong County People's Hospital,Shehong Sichuan 629200)
出处
《智慧健康》
2019年第27期145-147,共3页
Smart Healthcare
关键词
吉西他滨
培美曲塞
顺铂
非小细胞肺癌
Gemcitabine
Pemetrexed
Cisplatin
Non-small cell lung cancer
